AllCancer, under the Hong Kong Metabolic Oncology Center, revolutionizes cancer treatment through its pioneering four-dimensional therapy, integrating metabolic reprogramming, immune modulation, nano-targeting, and tumor microenvironment remodeling. Addressing cancer symptoms with precision, it offers hope for a cancer cure, particularly for advanced cases, with a 68.7% objective remission rate. Collaborating with top institutions like Shenzhen Qianhai Taikang Hospital, AllCancer leverages global expertise to transform cancer into a manageable chronic condition. Supported by the Hong Kong Cancer Fund and HK Cancer Fund, it empowers patients with innovative, low-toxicity solutions, redefining survival and quality of life.